Peptide Library

Human study PLS-00092

Prediction of Post-Acute-Sequelae of COVID-19 by Cargo Protein Biomarkers of Blood Total Extracellular Vesicles in Acute COVID-19.

Other design · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Prediction of Post-Acute-Sequelae of COVID-19 by Cargo Protein Biomarkers of Blood Total Extracellular Vesicles in Acute COVID-19.primary · The American journal of medicine · 2023-04-17 · PMID 37072092 · DOI

Design and participants

Design
Other design
Population
Age- and gender-matched participants: uninfected controls, acute COVID-19, post-acute sequelae of COVID-19 (PASC), and post-acute COVID without PASC
Conditions
COVID-19, Post-acute sequelae of COVID-19 (long COVID)
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported
Funding
NIH intramural research support (per publication type)

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Extracellular vesicle SARS-CoV-2 proteins indicate intracellular virus. Abnormal vesicle mitochondrial protein levels, including low MOTS-c, in acute infection predict high PASC risk and, in established PASC, indicate neuropsychiatric manifestations.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: MOTS-c was measured as an endogenous biomarker and not administered, so the study cannot inform effects of MOTS-c use.
    • small or imprecise: Group sizes in the abstract are small (for example n=8 and n=10), which limits the precision of the comparisons.
    • abstract only: Only the abstract of a brief report is available; the methods and full results are not in the record.
    • inappropriate population: MOTS-c was measured as an endogenous biomarker in COVID-19 patients and was not administered, so the study cannot address treatment effects.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 37072092, abstract (Conclusions, sentences 1-2) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 37072092, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 37072092, title (publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 37072092, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 37072092, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).